CEL-SCI Corp

CEL-SCI Corporation is a clinical-stage biotechnology company focused on research and development of immune-system-based treatments for cancer and other diseases in the United States. Its lead immunotherapy, Multikine, has completed Phase III clinical trials for the potential treatment of certain head and neck cancers. The company is also developing its Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process designed to stimulate the immune system against infections, autoimmune conditions, allergies, transplantation rejections, and cancer, and potentially to treat rheumatoid arthritis. Its LEAPS product candidates include CEL-2000, CEL-4000, and CEL-5000, which are in preclinical trials for potential rheumatoid arthritis treatments. CEL-SCI has a strategic partnership with Saudi Arabian Pharma Company for Multikine in head and neck cancer. Incorporated in 1983, the company is headquartered in Vienna, Virginia.